Founded in 2013, Flexus is a biotechnology company focused on the creation, development and commercialization of novel anti-cancer therapeutics. Toward this end, the company is leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression (ARTIS). This disruptive approach to cancer therapy targets that which is common to all tumors, the host immune system.

 

In contrast to conventional approaches, ARTIS:

 

• Target pathways relevant to many tumor types

• Enable the inherent ability of the immune system to destroy tumor cells

• Diminish tumor options for escape

• Enable broad patient response

 

Located in San Carlos, CA and funded by blue-chip investors including Kleiner Perkins Caufield and Byers (KPCB), The Column Group (TCG) and Celgene, Flexus has assembled a leadership team with a proven track record of success and an advisory group and team of scientists with unparalleled knowledge and deep expertise in the scientific, drug discovery and translational areas essential to execute on this approach.